Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026)

Verano Holdings' (VRNO) quarterly Net Income towards Common Stockholders came in at -$17.8 million in Q1 2026, down 54.78% year-on-year from -$39.4 million in Q1 2025, and up 90.28% on a QoQ basis from -$183.4 million in Q4 2025.

Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$17.8 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 54.78% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$264.2 million, a 24.2% increase from a year earlier, with the FY2025 full-year figure at -$257.9 million, up 24.56% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$17.8 million, up from -$183.4 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for VRNO reached as high as $45.9 million in Q1 2022 and fell as low as -$272.7 million in Q4 2024.
  • Historically, Net Income towards Common Stockholders has averaged -$56.4 million across 5 years, with a median of -$19.2 million in 2025.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
  • Year by year, Net Income towards Common Stockholders stood at -$216.1 million in 2022, then soared by 64.24% to -$77.3 million in 2023, then sank by 252.85% to -$272.7 million in 2024, then jumped by 32.74% to -$183.4 million in 2025, then soared by 90.28% to -$17.8 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$17.8 million in Q1 2026, -$183.4 million in Q4 2025, and -$43.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Verano Holdings 1.99 Bn 1.91 Bn 98.98 Mn -17.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.82 Mn
Dec 31, 2025 -183.41 Mn
Sep 30, 2025 -43.83 Mn
Jun 30, 2025 -19.15 Mn
Mar 31, 2025 -11.52 Mn
Dec 31, 2024 -272.71 Mn
Sep 30, 2024 -42.57 Mn
Jun 30, 2024 -21.76 Mn
Mar 31, 2024 -4.82 Mn
Dec 31, 2023 -77.29 Mn
Sep 30, 2023 -17.76 Mn
Jun 30, 2023 -13.06 Mn
Mar 31, 2023 -9.24 Mn
Dec 31, 2022 -216.11 Mn
Sep 30, 2022 -42.99 Mn
Jun 30, 2022 -9.85 Mn
Mar 31, 2022 45.87 Mn
Dec 31, 2021 -6.83 Mn
Sep 30, 2021 -11.96 Mn
Jun 30, 2021 -29.59 Mn